Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib plus cetuximab versus placebo plus cetuximab in previously treated KRAS wild-type metastatic colorectal cancer
ACTRN12607000589482Phase 3Recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Brivanib + cetuximab with Placebo + cetuximab (2 arms). Primary endpoint: Overall survival. Started Mar 2008; status: recruiting.
02
Drugs
brivanibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12607000589482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000589482.